Dianthus Therapeutics, Inc. officer Ryan Savitz filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 124,042 shares of common stock acquired through the exercise of stock options.

Key Highlights

  • Filer and role: Ryan Savitz, identified as an officer of Dianthus Therapeutics, Inc.
  • Shares proposed for sale: 124,042 shares of common stock, with an aggregate market value of $10,671,333.26.
  • Nature of acquisition: Securities to be sold were acquired through the exercise of stock options from the issuer on November 9, 2026, with cash payment.
  • Approximate date of sale: November 9, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Shares outstanding: 56,312,712 shares of common stock outstanding at the time of filing, according to the notice.
  • Rule 10b5-1 plan: The filing indicates a trading plan adoption date of August 7, 2026.
  • Prior sales: No securities of the issuer were sold by Savitz in the three months preceding this notice.

Dianthus Therapeutics Officer Files Rule 144 Notice for Option-Derived Shares

Ryan Savitz, an officer of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), submitted a Form 144 notice to the U.S. Securities and Exchange Commission on November 9, 2026, disclosing a proposed sale of 124,042 shares of Dianthus common stock. According to the filing, the shares carry an aggregate market value of $10,671,333.26 and represent a portion of the issuer's reported 56,312,712 shares outstanding.

The filing states that the securities to be sold were acquired on November 9, 2026, through the exercise of stock options granted by the issuer, with cash as the form of payment. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on the NASDAQ exchange. According to the remarks section of the filing, "The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale."

The notice also discloses that Savitz adopted a written trading plan under Rule 10b5-1 of the Securities Exchange Act on August 7, 2026. By signing the form and indicating that plan adoption date, Savitz represents, as of that date, that he was not aware of any material adverse information regarding the issuer that had not been publicly disclosed. The filing reports no securities of Dianthus sold by Savitz during the three months prior to this notice.

What Was Disclosed

Dianthus Therapeutics officer Ryan Savitz filed a Form 144 notice proposing the sale of 124,042 common shares with an aggregate market value of $10,671,333.26, acquired via stock option exercise, under a Rule 10b5-1 plan adopted August 7, 2026.